Phaseline

Companies › HCW Biologics

HCW Biologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HCW9302
IL-2 fusion protein
IL2Phase 1Alopecia Areata(AA)Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07049328HCW9302Phase 1Alopecia Areata(AA)ImmunologyJul 2027

From the company's SEC filings

Cash and short-term investments of $1m on 2026-06-30; operating cash outflow about $11m a year; runway about 1 months at that burn, to Jul 2026

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

IL2 (1)

Companies with the same targets

Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Coya Therapeutics Synthekine Nektar Therapeutics Asher Biotherapeutics Regeneron Pharmaceuticals Salspera Iovance Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.